Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 635

1.

Dietary tetrahydrocurcumin reduces renal fibrosis and cardiac hypertrophy in 5/6 nephrectomized rats.

Lau WL, Khazaeli M, Savoj J, Manekia K, Bangash M, Thakurta RG, Dang A, Vaziri ND, Singh B.

Pharmacol Res Perspect. 2018 Feb 19;6(2):e00385. doi: 10.1002/prp2.385. eCollection 2018 Apr.

PMID:
29468071
2.

Increments in serum high-density lipoprotein cholesterol over time are not associated with improved outcomes in incident hemodialysis patients.

Chang TI, Streja E, Soohoo M, Ko GJ, Rhee CM, Kovesdy CP, Kashyap ML, Vaziri ND, Kalantar-Zadeh K, Moradi H.

J Clin Lipidol. 2018 Jan 31. pii: S1933-2874(18)30030-8. doi: 10.1016/j.jacl.2018.01.010. [Epub ahead of print]

PMID:
29456130
3.

Novel RAS Inhibitors Poricoic Acid ZG and Poricoic Acid ZH Attenuate Renal Fibrosis via a Wnt/β-Catenin Pathway and Targeted Phosphorylation of smad3 Signaling.

Wang M, Chen DQ, Chen L, Liu D, Zhao H, Zhang ZH, Vaziri ND, Guo Y, Zhao YY, Cao G.

J Agric Food Chem. 2018 Feb 14. doi: 10.1021/acs.jafc.8b00099. [Epub ahead of print]

PMID:
29383936
4.

LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.

Suematsu Y, Jing W, Nunes A, Kashyap ML, Khazaeli M, Vaziri ND, Moradi H.

J Card Fail. 2018 Jan 8. pii: S1071-9164(18)30002-2. doi: 10.1016/j.cardfail.2017.12.010. [Epub ahead of print]

PMID:
29325796
5.

LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD.

Jing W, Vaziri ND, Nunes A, Suematsu Y, Farzaneh T, Khazaeli M, Moradi H.

Am J Transl Res. 2017 Dec 15;9(12):5473-5484. eCollection 2017.

6.

Iatrogenic iron overload and its potential consequences in patients on hemodialysis.

Rostoker G, Vaziri ND.

Presse Med. 2017 Dec;46(12 Pt 2):e312-e328. doi: 10.1016/j.lpm.2017.10.014. Epub 2017 Nov 16. Review.

PMID:
29153377
7.

The Leaky Gut and Altered Microbiome in Chronic Kidney Disease.

Lau WL, Vaziri ND.

J Ren Nutr. 2017 Nov;27(6):458-461. doi: 10.1053/j.jrn.2017.02.010.

8.

Molecular mechanisms of disorders of lipid metabolism in chronic kidney disease.

Moradi H, Vaziri ND.

Front Biosci (Landmark Ed). 2018 Jan 1;23:146-161.

PMID:
28930541
9.

Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites.

Zhang ZH, Mao JR, Chen H, Su W, Zhang Y, Zhang L, Chen DQ, Zhao YY, Vaziri ND.

Clin Biochem. 2017 Dec;50(18):1078-1086. doi: 10.1016/j.clinbiochem.2017.09.012. Epub 2017 Sep 18.

PMID:
28928007
10.

Increased Renal 2-Arachidonoylglycerol Level Is Associated with Improved Renal Function in a Mouse Model of Acute Kidney Injury.

Moradi H, Oveisi F, Khanifar E, Moreno-Sanz G, Vaziri ND, Piomelli D.

Cannabis Cannabinoid Res. 2016 Sep 1;1(1):218-228. doi: 10.1089/can.2016.0013. eCollection 2016.

11.

The nature, consequences, and management of neurological disorders in chronic kidney disease.

Jabbari B, Vaziri ND.

Hemodial Int. 2017 Aug 11. doi: 10.1111/hdi.12587. [Epub ahead of print] Review.

PMID:
28799704
12.

Treatment with dimethyl fumarate ameliorates liver ischemia/reperfusion injury.

Takasu C, Vaziri ND, Li S, Robles L, Vo K, Takasu M, Pham C, Farzaneh SH, Shimada M, Stamos MJ, Ichii H.

World J Gastroenterol. 2017 Jul 7;23(25):4508-4516. doi: 10.3748/wjg.v23.i25.4508.

13.

Risk of Postoperative Venous Thromboembolism Among Pregnant Women.

Suematsu Y, Obi Y, Shimomura A, Alizadeh RF, Vaziri ND, Nguyen NT, Stamos MJ, Ichii H.

Am J Cardiol. 2017 Aug 1;120(3):479-483. doi: 10.1016/j.amjcard.2017.04.053. Epub 2017 May 11.

14.

Role of RAS/Wnt/β-catenin axis activation in the pathogenesis of podocyte injury and tubulo-interstitial nephropathy.

Chen L, Chen DQ, Wang M, Liu D, Chen H, Dou F, Vaziri ND, Zhao YY.

Chem Biol Interact. 2017 Aug 1;273:56-72. doi: 10.1016/j.cbi.2017.05.025. Epub 2017 Jun 2.

PMID:
28578904
15.

Gene and protein expressions and metabolomics exhibit activated redox signaling and wnt/β-catenin pathway are associated with metabolite dysfunction in patients with chronic kidney disease.

Chen DQ, Cao G, Chen H, Liu D, Su W, Yu XY, Vaziri ND, Liu XH, Bai X, Zhang L, Zhao YY.

Redox Biol. 2017 Aug;12:505-521. doi: 10.1016/j.redox.2017.03.017. Epub 2017 Mar 23.

16.

The link between phenotype and fatty acid metabolism in advanced chronic kidney disease.

Chen DQ, Chen H, Chen L, Vaziri ND, Wang M, Li XR, Zhao YY.

Nephrol Dial Transplant. 2017 Jul 1;32(7):1154-1166. doi: 10.1093/ndt/gfw415.

PMID:
28339984
17.

Impact of iatrogenic iron overload on the course of hepatitis C in the dialysis population: A plea for caution.

Rostoker G, Vaziri ND.

Hemodial Int. 2017 Jun;21 Suppl 1:S68-S77. doi: 10.1111/hdi.12557. Epub 2017 Mar 23. Review.

PMID:
28332306
18.

Combined Clinical Phenotype and Lipidomic Analysis Reveals the Impact of Chronic Kidney Disease on Lipid Metabolism.

Chen H, Chen L, Liu D, Chen DQ, Vaziri ND, Yu XY, Zhang L, Su W, Bai X, Zhao YY.

J Proteome Res. 2017 Apr 7;16(4):1566-1578. doi: 10.1021/acs.jproteome.6b00956. Epub 2017 Mar 27.

PMID:
28286957
19.

Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients.

Chang TI, Streja E, Soohoo M, Kim TW, Rhee CM, Kovesdy CP, Kashyap ML, Vaziri ND, Kalantar-Zadeh K, Moradi H.

Clin J Am Soc Nephrol. 2017 Apr 3;12(4):591-602. doi: 10.2215/CJN.08730816. Epub 2017 Feb 13.

21.

Serum uric acid, protein intake and mortality in hemodialysis patients.

Park C, Obi Y, Streja E, Rhee CM, Catabay CJ, Vaziri ND, Kovesdy CP, Kalantar-Zadeh K.

Nephrol Dial Transplant. 2017 Oct 1;32(10):1750-1757. doi: 10.1093/ndt/gfw419.

PMID:
28064158
22.

Urea, a true uremic toxin: the empire strikes back.

Lau WL, Vaziri ND.

Clin Sci (Lond). 2017 Jan 1;131(1):3-12. Review.

23.

Gut hormones and gut microbiota: implications for kidney function and hypertension.

Afsar B, Vaziri ND, Aslan G, Tarim K, Kanbay M.

J Am Soc Hypertens. 2016 Dec;10(12):954-961. doi: 10.1016/j.jash.2016.10.007. Epub 2016 Nov 1. Review.

24.

Effect of resveratrol on progression of polycystic kidney disease: a case of cautious optimism.

Moradi H, Vaziri ND.

Nephrol Dial Transplant. 2016 Nov;31(11):1755-1758. Epub 2016 May 17. No abstract available.

PMID:
27190353
25.

Effects of end-stage renal disease and dialysis modalities on blood ammonia level.

Vaziri ND, Khazaeli M, Nunes ACF, Harley KT, Said H, Alipour O, Lau WL, Pahl MV.

Hemodial Int. 2017 Jul;21(3):343-347. doi: 10.1111/hdi.12510. Epub 2016 Nov 1.

26.

Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression.

Chen H, Cao G, Chen DQ, Wang M, Vaziri ND, Zhang ZH, Mao JR, Bai X, Zhao YY.

Redox Biol. 2016 Dec;10:168-178. doi: 10.1016/j.redox.2016.09.014. Epub 2016 Sep 28.

27.

Statins in Chronic Kidney Disease: When and When Not to Use Them.

Vaziri ND, Anzalone DA, Catini J.

J Fam Pract. 2016 Aug;65(8 Suppl). pii: supp_az_0816.

28.

Metabolomic Signatures of Chronic Kidney Disease of Diverse Etiologies in the Rats and Humans.

Zhang ZH, Chen H, Vaziri ND, Mao JR, Zhang L, Bai X, Zhao YY.

J Proteome Res. 2016 Oct 7;15(10):3802-3812. Epub 2016 Sep 28.

PMID:
27636000
29.

Associations of oxidative stress and inflammatory biomarkers with chemically-characterized air pollutant exposures in an elderly cohort.

Zhang X, Staimer N, Gillen DL, Tjoa T, Schauer JJ, Shafer MM, Hasheminassab S, Pakbin P, Vaziri ND, Sioutas C, Delfino RJ.

Environ Res. 2016 Oct;150:306-19. doi: 10.1016/j.envres.2016.06.019. Epub 2016 Jun 21.

30.

Safety Issues in Iron Treatment in CKD.

Vaziri ND.

Semin Nephrol. 2016 Mar;36(2):112-8. doi: 10.1016/j.semnephrol.2016.02.005. Review.

31.

Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.

Vaziri ND.

Kidney Int. 2016 Jul;90(1):41-52. doi: 10.1016/j.kint.2016.02.026. Epub 2016 Apr 26. Review.

32.

Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century.

Rostoker G, Vaziri ND, Fishbane S.

Drugs. 2016 May;76(7):741-57. doi: 10.1007/s40265-016-0569-0. Review.

33.

Hypertension as an autoimmune and inflammatory disease.

Solak Y, Afsar B, Vaziri ND, Aslan G, Yalcin CE, Covic A, Kanbay M.

Hypertens Res. 2016 Aug;39(8):567-73. doi: 10.1038/hr.2016.35. Epub 2016 Apr 7. Review.

34.

An integrated lipidomics and metabolomics reveal nephroprotective effect and biochemical mechanism of Rheum officinale in chronic renal failure.

Zhang ZH, Vaziri ND, Wei F, Cheng XL, Bai X, Zhao YY.

Sci Rep. 2016 Feb 23;6:22151. doi: 10.1038/srep22151.

35.

Resistant starch alters gut microbiome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats.

Kieffer DA, Piccolo BD, Vaziri ND, Liu S, Lau WL, Khazaeli M, Nazertehrani S, Moore ME, Marco ML, Martin RJ, Adams SH.

Am J Physiol Renal Physiol. 2016 May 1;310(9):F857-71. doi: 10.1152/ajprenal.00513.2015. Epub 2016 Feb 3.

36.

Effect of Synbiotic Therapy on Gut-Derived Uremic Toxins and the Intestinal Microbiome in Patients with CKD.

Vaziri ND.

Clin J Am Soc Nephrol. 2016 Feb 5;11(2):199-201. doi: 10.2215/CJN.13631215. Epub 2016 Jan 15. No abstract available.

37.

Lipidomics Biomarkers of Diet-Induced Hyperlipidemia and Its Treatment with Poria cocos.

Miao H, Zhao YH, Vaziri ND, Tang DD, Chen H, Chen H, Khazaeli M, Tarbiat-Boldaji M, Hatami L, Zhao YY.

J Agric Food Chem. 2016 Feb 3;64(4):969-79. doi: 10.1021/acs.jafc.5b05350. Epub 2016 Jan 25.

PMID:
26758241
38.

New Options for Iron Supplementation in Maintenance Hemodialysis Patients.

Vaziri ND, Kalantar-Zadeh K, Wish JB.

Am J Kidney Dis. 2016 Mar;67(3):367-75. doi: 10.1053/j.ajkd.2015.09.031. Epub 2015 Nov 24. Review.

39.

HDL abnormalities in nephrotic syndrome and chronic kidney disease.

Vaziri ND.

Nat Rev Nephrol. 2016 Jan;12(1):37-47. doi: 10.1038/nrneph.2015.180. Epub 2015 Nov 16. Review.

40.

Synthetic Triterpenoid RTA dh404 (CDDO-dhTFEA) Ameliorates Acute Pancreatitis.

Robles L, Vaziri ND, Li S, Masuda Y, Takasu C, Takasu M, Vo K, Farzaneh SH, Stamos MJ, Ichii H.

Pancreas. 2016 May-Jun;45(5):720-9. doi: 10.1097/MPA.0000000000000518.

41.

Metabolomics insights into chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosis.

Zhang ZH, Wei F, Vaziri ND, Cheng XL, Bai X, Lin RC, Zhao YY.

Sci Rep. 2015 Sep 28;5:14472. doi: 10.1038/srep14472.

42.
43.

The effect of Nrf2 pathway activation on human pancreatic islet cells.

Masuda Y, Vaziri ND, Li S, Le A, Hajighasemi-Ossareh M, Robles L, Foster CE, Stamos MJ, Al-Abodullah I, Ricordi C, Ichii H.

PLoS One. 2015 Jun 25;10(6):e0131012. doi: 10.1371/journal.pone.0131012. eCollection 2015.

44.

Association of serum lipids with outcomes in Hispanic hemodialysis patients of the West versus East Coasts of the United States.

Moradi H, Abhari P, Streja E, Kashyap ML, Shah G, Gillen D, Pahl MV, Vaziri ND, Kalantar-Zadeh K.

Am J Nephrol. 2015;41(4-5):284-95. doi: 10.1159/000381991. Epub 2015 May 30.

45.

The Gut as a Source of Inflammation in Chronic Kidney Disease.

Lau WL, Kalantar-Zadeh K, Vaziri ND.

Nephron. 2015;130(2):92-8. doi: 10.1159/000381990. Epub 2015 May 9. Review.

46.

Dose-dependent deleterious and salutary actions of the Nrf2 inducer dh404 in chronic kidney disease.

Vaziri ND, Liu S, Farzaneh SH, Nazertehrani S, Khazaeli M, Zhao YY.

Free Radic Biol Med. 2015 Sep;86:374-81. doi: 10.1016/j.freeradbiomed.2015.04.022. Epub 2015 Apr 28.

PMID:
25930007
47.

Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment.

Vaziri ND, Zhao YY, Pahl MV.

Nephrol Dial Transplant. 2016 May;31(5):737-46. doi: 10.1093/ndt/gfv095. Epub 2015 Apr 16. Review.

PMID:
25883197
48.

Lipidomics: new insight into kidney disease.

Zhao YY, Vaziri ND, Lin RC.

Adv Clin Chem. 2015;68:153-75. doi: 10.1016/bs.acc.2014.11.002. Epub 2015 Jan 7. Review.

PMID:
25858872
49.

The Chronic Kidney Disease - Colonic Axis.

Pahl MV, Vaziri ND.

Semin Dial. 2015 Sep-Oct;28(5):459-63. doi: 10.1111/sdi.12381. Epub 2015 Apr 9.

50.

Green tea polyphenol (-)-epigallocatechin-3-gallate restores Nrf2 activity and ameliorates crescentic glomerulonephritis.

Ye T, Zhen J, Du Y, Zhou JK, Peng A, Vaziri ND, Mohan C, Xu Y, Zhou XJ.

PLoS One. 2015 Mar 18;10(3):e0119543. doi: 10.1371/journal.pone.0119543. eCollection 2015.

Supplemental Content

Loading ...
Support Center